PLANNED MAINTENANCE

There will be scheduled maintenance work beginning on Wednesday 26th February 2020 from 11:00 AM through to 12.00 PM (GMT).

During this time, you may not be able to log into ChemSpider. We apologise for any inconvenience this might cause and thank you for your patience.

ChemSpider 2D Image | N-[4-({3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-6-quinazolinyl]acrylamide | C24H18ClFN4O2

N-[4-({3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-6-quinazolinyl]acrylamide

  • Molecular FormulaC24H18ClFN4O2
  • Average mass448.877 Da
  • Monoisotopic mass448.110229 Da
  • ChemSpider ID25027184

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

2-Propenamide, N-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- [ACD/Index Name]
N-[4-({3-Chlor-4-[(3-fluorbenzyl)oxy]phenyl}amino)-6-chinazolinyl]acrylamid [German] [ACD/IUPAC Name]
N-[4-({3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-6-quinazolinyl]acrylamide [ACD/IUPAC Name]
N-[4-({3-Chloro-4-[(3-fluorobenzyl)oxy]phényl}amino)-6-quinazolinyl]acrylamide [French] [ACD/IUPAC Name]
N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide
[897383-62-9]
1050500-29-2 [RN]
897383-62-9 [RN]
Allitinib
AST 1306
More...
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective f or ErbB family than other kinases. MedChem Express
      AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.; IC50 value: 0.5/3 nM (EGFR/Erb2)[1]; Target: EGFR/Erb2;Mutant EGFR T790M/L858R; AST-1306 functions as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, respectively. MedChem Express HY-15375
      AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.;IC50 value: 0.5/3 nM (EGFR/Erb2)[1];Target: EGFR/Erb2;Mutant EGFR T790M/L858RAST-1306 functions as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, respectively. Further studies showed that AST-1306 inactivated pathways downstream of these receptors and thereby inhibited the proliferation of a panel of cancer cell lines. AST-1306 is a potent(pM) and selective inhibitor of EGFR and ErbB4 (IC50 = 500pM and 800 pM, respectively). AST-1306 blocks phosphorylation of EGFR and also prevents downstream pathways. AST-1306 also dose-dependently inhibits EGF-induced EGFR phosphorylation in the A549 cancer cell line. MedChem Express HY-15375
      EGFR MedChem Express HY-15375
      JAK/STAT Signaling MedChem Express HY-15375
      JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; MedChem Express HY-15375

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module

Density: 1.4±0.1 g/cm3
Boiling Point: 655.0±55.0 °C at 760 mmHg
Vapour Pressure: 0.0±2.0 mmHg at 25°C
Enthalpy of Vaporization: 96.5±3.0 kJ/mol
Flash Point: 349.9±31.5 °C
Index of Refraction: 1.700
Molar Refractivity: 124.3±0.3 cm3
#H bond acceptors: 6
#H bond donors: 2
#Freely Rotating Bonds: 7
#Rule of 5 Violations: 1
ACD/LogP: 5.02
ACD/LogD (pH 5.5): 4.96
ACD/BCF (pH 5.5): 3068.63
ACD/KOC (pH 5.5): 9405.28
ACD/LogD (pH 7.4): 5.18
ACD/BCF (pH 7.4): 5116.81
ACD/KOC (pH 7.4): 15682.89
Polar Surface Area: 76 Å2
Polarizability: 49.3±0.5 10-24cm3
Surface Tension: 60.6±3.0 dyne/cm
Molar Volume: 321.6±3.0 cm3

Click to predict properties on the Chemicalize site


Advertisement